Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma
Shaofang Wu, Xiaolong Li, Feng Gao, et al.
Neuro-Oncology (2021) Vol. 23, Iss. 6, pp. 920-931
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
Manendra Singh Tomar, Ashok Kumar, Chhitij Srivastava, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188616-188616
Closed Access | Times Cited: 201
Redox regulation: mechanisms, biology and therapeutic targets in diseases
Bowen Li, Hui Ming, Siyuan Qin, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma
Konstantinos Gousias, Theocharis Theocharous, Matthias Simon
Biomedicines (2022) Vol. 10, Iss. 3, pp. 564-564
Open Access | Times Cited: 53
Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study
Yawen Yu, Aiping Wang, Siqi Wang, et al.
Molecular Pharmaceutics (2022) Vol. 19, Iss. 4, pp. 1219-1229
Closed Access | Times Cited: 41
Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM
Bao Liu, Qifeng Ji, Ying Cheng, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 39
The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer
Qingming Fang
Cancers (2024) Vol. 16, Iss. 2, pp. 331-331
Open Access | Times Cited: 12
Integration of Demethylation-Activated DNAzyme with a Single Quantum Dot Nanosensor for Sensitive Detection of O6-Methylguanine DNA Methyltransferase in Breast Tissues
Yun Han, Dongling Li, Qian Han, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 11, pp. 4487-4494
Closed Access | Times Cited: 9
LAMB1 downregulation suppresses glioma progression by inhibiting aerobic glycolysis through regulation of the NF-κB/HK2 axis
Zhenxiang Zhao, Haiying Liu, Yingzi Liu, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study
Mateusz Szylberg, Paweł Sokal, Paulina Śledzińska, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 2030-2030
Open Access | Times Cited: 37
Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway
Qingfa Tang, Haihong Cao, Ni Tong, et al.
Phytomedicine (2022) Vol. 99, pp. 154016-154016
Closed Access | Times Cited: 35
Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications
Bernd Kaina
Journal of Clinical Medicine (2023) Vol. 12, Iss. 23, pp. 7442-7442
Open Access | Times Cited: 17
EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma
Eryan Yang, Biao Hong, Yunfei Wang, et al.
Cancer Letters (2024) Vol. 588, pp. 216812-216812
Closed Access | Times Cited: 7
Muscone restores anoikis sensitivity in TMZ-resistant glioblastoma cells by suppressing TOP2A via the EGFR/Integrin β1/FAK signaling pathway
Yuheng Zou, Lanyang Xu, Wanyu Wang, et al.
Phytomedicine (2024) Vol. 129, pp. 155714-155714
Closed Access | Times Cited: 7
Blood-brain barrier penetrating nanosystems enable synergistic therapy of glioblastoma
Yajing Sun, Ming Li, Meng Zheng, et al.
Nano Today (2024) Vol. 56, pp. 102310-102310
Open Access | Times Cited: 7
Connexin 43 confers chemoresistance through activating PI3K
Kevin J. Pridham, Farah Shah, Kasen R. Hutchings, et al.
Oncogenesis (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 26
Fatty acid synthase: a druggable driver of breast cancer brain metastasis
Javier A. Menéndez, Ruth Lupu
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 427-444
Closed Access | Times Cited: 24
Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models
Lisa Gherardini, Veronica Vetri Buratti, Mirko Maturi, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 16
Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma
Nana Wang, Jiejun Wang, Pu Wang, et al.
Analytical Chemistry (2023) Vol. 95, Iss. 31, pp. 11567-11571
Open Access | Times Cited: 14
Expert opinion on translational research for advanced glioblastoma treatment
Xiaoteng Cui, Yunfei Wang, Junhu Zhou, et al.
Cancer Biology and Medicine (2023), pp. 1-9
Open Access | Times Cited: 13
Research progress of anti-glioma chemotherapeutic drugs (Review)
Yi-Shu Zhou, Wei Wang, Na Chen, et al.
Oncology Reports (2022) Vol. 47, Iss. 5
Open Access | Times Cited: 22
Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development
Priya Bisht, Vikash Kumar, Ruchi Pandey, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 19
Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma
Yatian Li, Zhenyue Gao, Yuhong Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 11
MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell
Zheng Yuan, Meixia Guo, Yue Zhang, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist’s perspective
Yajun Jiang, Wen Gao
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patients
Huanming Shen, Zhi Zhou, Xiaoni Zhang, et al.
Journal of Neuro-Oncology (2025)
Closed Access
Page 1 - Next Page

Scroll to top